Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127242401 | 12724240 | 1 | I | 20160830 | 20160908 | 20160908 | EXP | SK-009507513-1609SVK000090 | MERCK | 64.00 | YR | F | Y | 0.00000 | 20160908 | OT | SK | SK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127242401 | 12724240 | 1 | PS | JANUMET | METFORMIN HYDROCHLORIDESITAGLIPTIN PHOSPHATE | 1 | Oral | 1 DF, BID | U | 22044 | 1 | DF | FILM-COATED TABLET | BID | |||||
| 127242401 | 12724240 | 2 | C | candesartan cilexetil (+) hydrochlorothiazide | CANDESARTAN CILEXETILHYDROCHLOROTHIAZIDE | 1 | UNK | 0 | |||||||||||
| 127242401 | 12724240 | 3 | C | AFLAMIL | 2 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127242401 | 12724240 | 1 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127242401 | 12724240 | HO |
| 127242401 | 12724240 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127242401 | 12724240 | Lactic acidosis | |
| 127242401 | 12724240 | Pulmonary embolism | |
| 127242401 | 12724240 | Renal failure | |
| 127242401 | 12724240 | Respiratory failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |